Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, has appointed Angèle Maki, PhD, as Chief Business Officer (CBO).

Experience

Maki brings over 20 years of biopharmaceutical industry experience, including leadership roles in business development, licensing, and corporate venture across both emerging biotech ventures and global pharmaceutical companies. Her background includes senior positions at Medarex (now part of Bristol Myers Squibb), Genentech, Merck & Co., Eli Lilly and Company, and Callio Therapeutics.

In her new role, Maki will lead Ability’s business development strategy, driving global partnering efforts and cultivating new investor relationships to support the company’s growth. These strategic collaborations and financing initiatives will help advance autoimmune and oncology programs created with Ability’s proprietary AbiLeap platform toward the clinic, while unlocking its potential to generate new, highly specific, logic-gated antibody therapies across multiple indications.

“I am very excited to join Ability Biotherapeutics at this pivotal stage of growth,” said Dr. Maki. “Ability’s bold mission to revolutionize antibody therapies through its unique logic-gated approach, supported by generative AI and one of the largest human antibody databases, is immensely compelling. I look forward to contributing to the company’s continued success as it moves toward first-in-human studies and seeks to have a meaningful impact for patients.”